TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07438405: An Open-label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-sponsored AMG 732 Studies and Are Primary Proptosis Non-responders or Who Relapsed During the Safety Follow-up

Sponsor: Amgen · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$3,087,600

Rescue Site Savings

+$2,025,200

Unlock Full NCT07438405 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07438405 Rescue Dossier →